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ABSTRACT 
Molecular biology techniques are routinely used to diagnose and monitor 
treatment of patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections. These tools can detect and quantify viral genomes, and analyze their 
sequence, in order to determine their genotype or subtype and to identify nucleotide or 
amino acid substitutions associated with resistance to antiviral drugs. They include real-
time target amplification methods, which have been standardized and are widely used in 
clinical practice to diagnose and monitor HBV and HCV infections, and next-generation 
sequencing techniques, which are still restricted to research laboratories. In addition, 
new enzyme immunoassays can quantify hepatitis B surface and hepatitis C core 
antigens, and point-of-care tests and alternatives to biologic tests that require whole-
blood samples obtained by venipuncture have been developed. We review these new 
virologic methods and their clinical and research applications to HBV and HCV 
infections. 
 
Keywords: diagnostic assay, real-time PCR, real-time TMA, next-generation sequencing, 
antigen quantification, point-of-care tests 
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Virology techniques developed over the past 20 years are routinely used to 
diagnose and monitor chronic viral infections, such as those caused by hepatitis B virus 
(HBV) and hepatitis C virus (HCV). Molecular biology tools can be used to detect and 
quantify viral genomes, sequence them, assign them to a phylogenic clade or subclade 
(genotype or subtype), and identify clinically relevant nucleotide or amino acid 
substitutions, such as those associated with resistance to antiviral drugs. Recent 
advances include real-time target amplification methods for detecting and quantifying 
viral genomes and next-generation sequencing (NGS) techniques. Other new assays 
detect and quantify viral antigens, whereas point-of-care tests and alternatives to 
biologic tests that require whole-blood samples have been developed. We review these 
methods and how they might be used to diagnose, treat, and manage patients with HBV 
or HCV infection. 
 
NEW METHODS FOR QUANTIFYING HBV DNA AND HCV RNA 
HCV and HBV genomes must be detected and quantified before treatment 
decisions can be made and to monitor antiviral therapy. The viral genomes can be 
detected and quantified using target amplification methods, such as the PCR and 
transcription-mediated amplification (TMA), and with signal amplification methods, 
such as hybrid-capture and the branched DNA assay. Recently developed real-time 
target amplification methods have improved viral genome detection and quantification 
for clinical and research purposes. 
 
Target Amplification Methods  
First-generation target amplification techniques have been widely used to 
diagnose HBV and HCV infections and to monitor responses to antiviral therapies. In 
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PCR or TMA assays, amplicons are detected at the end of the amplification process by 
their specific hybridization to immobilized oligonucleotide probes; the amplicon–probe 
hybrids are detected by an enzymatic reaction. They are quantified based on 
competitive amplification of the viral template with a known amount of synthetic 
standard added to each reaction tube; the relative amounts of viral template and 
standard amplicons are measured and the results are interpreted with a standard curve 
established in parallel.  
Because amplification reactions are saturable, these methods have a narrow 
dynamic range of quantification. As a result, high levels of virus are not always 
accurately quantified and require reanalysis after samples are diluted, whereas low 
levels of virus (such as in patients receiving antiviral therapy) are often not detectable. 
This problem was solved by development of real-time target amplification techniques in 
which quantification takes place during the exponential phase of the amplification 
reaction. In addition, the reaction is run in a closed system, which prevents carryover 
contamination and improves specificity. 
 
Real-Time Target Amplification 
Real-Time PCR 
PCR uses several temperatures and a thermostable DNA polymerase to generate 
double-stranded DNA amplicons. In assays for HBV, nucleic acids are isolated from a 
sample and the HBV DNA is directly amplified by PCR. Assays for HCV require reverse 
transcription of HCV RNA, to synthesize complementary DNA, which is used as template 
in the PCR reaction. Each complete PCR cycle doubles the number of DNA copies. The 
principle of real-time PCR is to detect amplicon synthesis during the PCR reaction and 
thereby deduce the starting amount of viral genome in a clinical sample. A fluorescent 
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probe is linked to a quencher and annealed to the target sequence, between the sense 
and antisense PCR primers. During each PCR reaction, as the DNA polymerase extends 
the primer, its intrinsic nuclease activity degrades the probe, releasing the reporter 
fluorochrome. The amount of fluorescence released during the amplification cycle and 
detected by the system is proportional to the amount of amplicons generated in each 
PCR cycle. Software is used to calculate the threshold cycle in each reaction (Ct), which 
has a linear relationship with the initial amount of nucleic acid. In each PCR run, parallel 
processing of a panel of quantified standards is used to establish a standard curve for 
quantification. 
 
Real-Time TMA 
The TMA reaction is isothermal and uses 2 enzymes—a reverse transcriptase and 
a T7 RNA polymerase. The amplicons consist of single-stranded RNA. After lysis of the 
viral envelope, the viral genome (HBV DNA or HCV RNA) is captured by oligonucleotide 
probes and bound to magnetic microparticles. Amplification involves autocatalytic 
isothermal production of RNA transcripts with the 2 enzymes. Each newly synthesized 
RNA re-enters the TMA process and serves as a template for the next round of 
replication, resulting in exponential amplification of the target RNA. The amplicons 
created during amplification are detected in real time, using probes that contain a 
reporter dye (fluorophore) and a quencher. In the absence of amplicons, these probes 
exist in a closed configuration, and the fluorescence output of the fluorophore is 
quenched because it is in close proximity to the quencher. During amplification, when 
these probes bind to amplicons, the fluorophore and quencher are separated and the 
fluorescent signal is generated. Software is used to calculate the amount of viral genome 
in the initial sample by comparison with a panel of quantified standards. 
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Available Methods 
Table 1 shows the performance of current and upcoming commercial real-time 
PCR and TMA assays. These assays accurately quantify HBV DNA and HCV RNA in 
clinical practice.1-5 The first-generation Cobas Ampliprep®/Cobas Taqman® assay 
substantially underestimated levels of HCV RNA in approximately 30% of patients 
infected with HCV genotype 4, and occasionally failed even to detect this genotype, due 
to nucleotide polymorphisms at the hybridization site of the PCR primers or TaqMan 
probe (in the 5’ non-coding region of the HCV genome).1, 3, 6, 7 This issue has been 
resolved in the second-generation assay, scheduled for release in 2012.8 
These assays avoid false-positive that result from carryover contamination. They 
are fully or partly automated (in the latter case, the extract has to be transferred for 
automated PCR amplification and quantification, after automated extraction). These 
techniques are recommended to quantify HBV DNA and HCV RNA in international liver 
society guidelines.9-14 
 
Future Needs 
The advent of real-time PCR and TMA methods has resolved many of the 
problems of quantifying HBV DNA and HCV RNA in clinical practice. HBV DNA assays 
need further improvement, to increase their upper limit of quantification—clinicians 
frequently encounter patients (particularly those that are immunotolerant) with levels 
of HBV DNA much higher than 108 international units (IU)/mL.  
There were confusing results from recent phase 2 and 3 clinical trials of direct 
acting antiviral (DAA) agents against HCV, administered with or without pegylated IFN-
α and ribavirin, according to the use of the lower limit of detection (LLOD) or the lower 
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limit of quantification (LLOQ) defined by the assay manufacturers to assess the on-
treatment virologic response and to predict sustained virologic response (SVR). In trials 
of pegylated IFN-α, ribavirin, and telaprevir or boceprevir, HCV RNA levels below the 
LLOD (at weeks 4, 8, or 12, depending on the protease inhibitor) were reported to be 
more predictive of SVR than HCV RNA levels below the LLOQ.15, 16 However, the LLOQ is, 
by definition, accurate and reproducible, because it is within the dynamic range of 
quantification, whereas the LLOD is defined statistically and the actual amount of HCV 
RNA it indicates varies among patients and samples. Therefore, the LLOD is not suitable 
for making individual therapeutic decisions. Future assays should have identical LLOD 
and LLOQ values, to ensure accurate definition of undetectable levels of HCV RNA. In the 
meantime, new time points should be defined for accurate assessment using the LLOQ. 
 
NEW SEROLOGIC METHODS  
HBsAg Quantification 
The level of hepatitis B surface antigen (HBsAg) has been proposed as a marker 
of infected liver mass or the amount of covalently closed circular DNA, the episomal 
form of HBV, which persists in hepatocytes. Combined analysis of HBsAg and HBV DNA 
levels can be used to identify inactive carriers and monitor response to therapy.17-20 Two 
commercial enzyme immunoassays are available; they have narrow dynamic ranges of 
quantification, so samples that contain high levels of HBsAg must often be retested after 
being diluted. The HBsAg assay on Architect® system (Abbott Diagnostics; Abbott Park, 
Illinois) has a dynamic range of quantification of 0.05–250.00 IU/mL (maximum 
authorized dilution, 1:999), whereas the HBsAg II Quant assay on Elecsys® or Cobas® e 
devices (Roche Diagnostics GmbH; Mannheim, Germany) has a dynamic range of 
quantification of 0.05–130.00 IU/mL (no recommendation for maximum dilution). Both 
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assays are European Conformity (CE)-marked, but they have not been approved by the 
FDA and are available for research use only in the United States. The assays are 
inexpensive, easy to perform, and accurately quantify HBsAg in all HBV genotypes.21, 22  
 
HCV Core Antigen Detection and Quantification 
Levels of HCV core antigen correlate with levels of HCV RNA in patients with 
chronic HCV infection.23-26 Assays that quantify HCV core antigen can therefore be used 
as alternatives to those that measure levels of HCV RNA, as shown in various 
populations of patients.23, 27-29 The Architect® HCV Ag assay (Abbott Diagnostics) is 
commercially available. Its dynamic range of quantification is 3.0–20,000 fmol/L. This 
assay is CE-marked but has not been approved by the FDA and is available for research 
use only in the United States. It is less expensive and easier to use than current HCV RNA 
tests for diagnosis of chronic hepatitis C and monitoring of antiviral therapy. However, 
the HCV Ag assay’s LLOD corresponds to HCV RNA levels of 500–3000 IU/mL, 
depending on the HCV genotype.30 Assays for HCV core antigen are therefore not 
suitable for response-guided therapy, according to current guidelines. 
 
POINT-OF-CARE TESTS AND ALTERNATIVES TO BIOLOGIC TESTS THAT REQUIRE 
WHOLE-BLOOD SAMPLES  
Point-of-care tests are used directly at the site of patient care, outside of the 
biology laboratory. They include immunoassays based on agglutination, 
immunochromatography or immunofiltration, as well as assays for nucleic acid 
detection and quantification. Point-of-care tests can be particularly useful for large-scale 
screening and improving access to care in regions without molecular biology 
laboratories. 
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Alternatives to biologic tests that require whole-blood samples, obtained by 
venipuncture, are being developed. They can use original specimen matrices, such as 
oral fluids or blood collected from a finger stick into a capillary tube. Blood can be 
collected on filter paper, known as the dried blood spot (DBS) method, which makes it 
possible to store desiccated samples for transport as non-hazardous material via regular 
mail or courier services. DBS collection and storage is easy and, although standard 
procedures must be carefully followed, little training is required for preparation. HBV 
DNA and HCV RNA can be detected and quantified from DBS by classic or real-time PCR 
methods, although at a cost of reduced analytical sensitivity, compared to the whole 
blood-based methods described above. The reduction in sensitivity results from small 
input volumes, less-efficient nucleic acid extraction, and nucleic acid degradation in 
extreme storage conditions. One study reported that the limit of detection of HBV DNA 
from DBS was approximately 1 Log10 higher than from serum samples. There was a high 
level of concordance in HBV genotype analysis of DBS and serum samples, and also in 
detection of precore mutants and drug-resistant variants.31 In another report, the 
detection limit for HCV RNA in DBS was about 1000 IU/mL. Concordant results were 
also obtained from HCV quantification and genotype analyses of serum and DBS.32 In 
theory, the analytical sensitivity of viral genome detection from DBS could reach levels 
similar to those obtained from serum and plasma samples, as recently shown for HIV.33 
Any serum marker, including HBsAg and HCV core antigen, could also be detected and 
quantified from DBS. However, this has not been tested yet. 
 
NGS 
Viral genome sequence analysis can be used to determine HBV or HCV genotype, 
assess mutations in the HBV core or core promoter, and identify amino acid 
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substitutions responsible for resistance to antiviral agents. DNA sequence analysis has 
been based for many years on the chain termination method, described by Sanger et al.34 
NGS methods offer new opportunities but also create new challenges, because they 
generate large amounts of data and their results can often be difficult to interpret.  
 
Sequencing Techniques  
The Sanger method has been improved by the inclusion of fluorescent labels and 
capillary electrophoresis.35, 36 This technique involves DNA denaturation, annealing, and 
elongation. During elongation, DNA polymerase randomly incorporates 
deoxynucleotides (dNTP) or dideoxynucleotides (ddNTP) that have been labeled with 
different fluorochromes, resulting in chain elongation or termination, respectively. 
Chains of different lengths are therefore generated, each ending with a labeled 
nucleotide. The amplicons are then migrated in a capillary system that separates them 
according to their lengths. Bioinformatic software measures the fluorescence peak at 
each position of the analyzed sequence and identifies the corresponding ddNTP to 
determine a consensus sequence. The presence of multiple peaks at the same position 
indicates a mixed sequence. 
The Sanger sequencing method is well suited for detecting small numbers of 
substitutions in known genes, but it cannot be used to sequence large portions of plant 
or animal genomes for genome-wide association studies (GWAS),37-39 or to sequence 
large amounts of targets for gene expression profiling (RNA-Seq).40 
Viruses that establish chronic infections, such as HIV, HBV, and HCV, behave as 
quasispecies—complex mixtures of genetically related but distinct viral populations in 
equilibrium in a given replicative environment (Figure 1). For this reason, at any given 
time, patients carry a large number of different viral genome sequences. Classic 
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sequencing techniques can only identify the consensus sequence of a viral quasispecies 
at a given time point, whereas most intermediate and minor viral populations go 
undetected. In addition, this approach cannot link different substitutions present in the 
same viral variant or distinguish substitutions present in different variants. PCR 
products can be cloned and sequenced to identify intermediate virus populations and 
linked substitutions, but this approach is cumbersome and time-consuming and has 
therefore been restricted to the research setting. 
 
Principles of NGS  
NGS methods have been recently developed to increase sequencing capacity 
while generating clonal sequences. Current NGS methods use a 3-step sequencing 
process: library preparation, DNA capture and enrichment, and sequencing (Figure 2).41 
In library preparation, DNAs of appropriate lengths are prepared and labeled with the 
primers required for subsequent isolation and sequencing. DNA is then captured and 
clonal DNA is enriched (this step is not required with Pacific Biosciences technology). 
The DNA is then sequenced, via polymerization combined with detection based on 
pyrophosphate (pyrosequencing), H+ ions (pH variation) or fluorescence, or ligation 
combined with fluorescence detection. The detected signals are transformed into 
readable sequences by an integrated browser and specific software, to produce 
biologically relevant information. 
 
NGS Methods 
NGS technologies developed by various manufacturers (Table 2) include high-
capacity systems, such as the Genome Analyzer, HiSeq sequencers (Illumina Inc., San 
Diego, California), and 5500 series sequencers, which use SOLiD technology (Applied 
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Biosystems, Carlsbad, California) and long-read sequencers, such as the Genome 
Sequencer (GS) FLX or Junior (454 Life Sciences, Roche Diagnostics Corp., Branford, 
Connecticut), Ion Torrent (Applied Biosystems) and PacBio RS (Pacific Biosciences, Gen-
Probe, Menlo Park, California). 
The Illumina technology fragments DNA and then tags the fragments with 
primers that are complementary to probes, to allow fixation on a flow cell. Clonal DNA is 
then enriched by PCR, to generate clusters of amplicons, and sequenced, through 
polymerization with fluorescent dNTPs.42 The SOLiD system (Applied Biosciences) uses 
emulsion PCR (emPCR) to enrich clonal DNAs fixed to microbeads. The beads are then 
transferred to a flow chip and DNA is sequenced by ligation with fluorescent primers.43 
These 2 technologies generate millions of short reads (Table 2). They are well suited to 
resequencing when a reference sequence is available (human genome or transcriptome) 
and the read length of 100–150 bp is sufficient to identify a known gene, for example in 
GWAS or RNA-seq studies. These technologies can also be used to identify individual 
substitutions in viral genes, such as those associated with drug resistance. Analysis of a 
large number of sequences (corresponding to the depth of the reaction) ensures high 
levels of sensitivity for minor viral variants. However, short reads cannot be used to 
establish linkages between substitutions located on the same viral variants, which is 
required for viral resistance studies. 
The long-read sequencers have more limited sequencing capacities but generate 
longer sequences. In the GS-based technology, DNA is labeled and clonally enriched by 
emPCR at the surface of microbeads, which are then loaded in picotiter plates containing 
over a million wells. During the pyrosequencing reaction, light is emitted every time a 
new base is inserted by polymerization.44 The Ion Torrent technology is technically close 
to the GS technique, but emPCR amplicons are loaded on a semiconductor sequencing 
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chip; the addition of nucleotides during the polymerization reaction generates H+ ions, 
which induce local pH changes that are detected and measured.45 The PacBio RS 
technology is substantially different. After preparation of the DNA library, unamplified 
DNAs are transferred to an optical system, called a zero-mode waveguide, which 
amplifies fluorescence emitted during polymerization. In this technique, fluorescent 
signals from each clonal DNA molecule, processed by thousands of polymerase 
molecules fixed to the zero-mode waveguide, are detected without the need for prior 
amplification.46 This group of sequencers generates smaller numbers of sequences, but 
their length is suitable for linkage studies and de novo characterization of genomic 
sequences for which no reference sequence is available. They are therefore well suited 
to virology studies. 
 
Limitations of NGS Methods 
All existing methods are susceptible to generating sequencing errors. Evaluations 
of the Genome Analyzer, 5500 sequencer and GS FLX have calculated accuracy values of 
96.7%–100%—similar to those of the classic Sanger method (Table 2).47 However, there 
is controversy about the actual error rates of these methods, so prospective assessments 
are required by independent investigators. 
NGS methods generate unreadable sequences (called junk data) at variable rates. 
For instance, these rates appear to be high with SOLiD technology on the 5500 
sequencer.47-50 This is associated with an overcost but not with lower-quality final 
results, because these sequences can be easily identified and removed. False-positive or 
false-negative results for substitutions have been reported at higher rates with Illumina 
technology than the SOLiD and GS FLX technologies.47, 50 They are easily corrected when 
 15 
the sequencing depth is high, as in GWAS or gene expression profiling studies, but are 
problematic for studies of rare variants.  
Performance can be affected by AT- or GC-rich regions, especially with the 
Illumina and SOLiD technologies, leading to low overall resolution of genome 
sequences.51 For the detection of insertions or deletions (indels), the GS-FLX system has 
been shown to provide the best performance,47, 52 but it performs less well in 
homopolymeric regions, where it has high rates of error.51, 53 
 
Analyzing NGS Data 
In the first step of NGS data analysis, signals generated by the sequencing 
reaction are converted into readable sequences by proprietary base-caller software. At 
the end of this step, data are composed of sequences in FASTA format, along with quality 
scores for each nucleotide of each sequence. The most frequently used format is the 
PHRED quality score,54-56 which is based on base-calling error probabilities.  
In the second part of the analysis, the large number of generated sequences must 
be processed into comprehensible biologic data by software, through 3 steps that 
depend on the type of study and sample analyzed.57 The goal of the first step is to 
classify and format sequences into readable data. In the second step, unreliable 
sequences are eliminated, including sequences with a Phred quality score below 20 (1% 
risk of base-caller error)58 and excessively short sequences (the precise cut-off depends 
on the technology used). The third step, sequence alignment, is critical and particularly 
difficult for viral sequences, because of the level of natural genetic variation (numerous 
substitutions or indels, relative to reference sequences) and the coexistence of 
numerous viral populations with different sequences. A number of alignment algorithms 
have been developed but were found to generate different alignments and generally fail 
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to take into consideration the specificities of viral infections.59-64 Additional alignment 
quality filters are therefore needed. This part of the analysis must ultimately generate a 
set of formatted sequences that can be used with confidence for specific analyses and to 
generate clinically meaningful information. 
We recently developed in-house software to model the dynamics of viral 
populations during and after antiviral therapy and characterize drug resistance.64-66 This 
software package has been used to demonstrate the preexistence of amino acid 
substitutions that confer HBV and HCV resistance to specific antiviral drugs. It has also 
been used to characterize the complex dynamics of sensitive and resistant viral 
populations in patients with chronic hepatitis B treated with adefovir and in patients 
with chronic hepatitis C treated with telaprevir combined with pegylated IFN-, with or 
without ribavirin.64, 65 
 
Future Needs 
The main advantage of NGS techniques for studying chronic viral infections is 
their improved depth, relative to the Sanger method—this ensures that minor viral 
populations that are of possible clinical significance are sequenced. No further 
improvements in depth appear to be needed, because existing technologies can detect 
minor viral populations in complex quasispecies mixtures. However, the clinical 
significance of small viral populations is not clear. In addition, it is still difficult to 
distinguish between true substitutions and errors generated by the sequencing reaction, 
so specificity needs to be improved.  
Sequence length is an important factor in identifying linkages between different 
substitutions located on the same viral strand. Full-length viral genome analysis will 
improve our understanding of the dynamics of viral populations in different clinical 
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circumstances. Reading lengths will need to be extended considerably to meet this need 
(the HBV genome contains approximately 3000 bp, the HCV genome 10,000 bp).  
Currently, the main need is for bioinformatic tools to analyze NGS sequences in 
the context of viral infections. Complex tools might be suitable for research purposes, 
but clinicians will require bioinformatic tools that can translate millions of generated 
sequences into simple, clinically relevant information on which therapeutic decisions 
can be made. 
 
CLINICAL USE OF VIROLOGIC TOOLS  
HBV Infection 
Tests that are useful for patients with HBV infection include enzyme 
immunoassays that detect HBV antigen and antibodies, assays that detect and quantify 
HBV DNA, and methods that identify amino acid substitutions associated with HBV 
resistance to nucleoside/nucleotide analogues. There is debate over the value of assays 
that quantify HBsAg. Tools that determine HBV genotype or identify core and core 
promoter mutants are valuable for research but have no clinical use.  
 
Diagnosis and Prognosis 
Chronic HBV carriers are defined by the persistence of HBsAg in their blood for 
more than 6 months. Chronic hepatitis B is characterized by a level of HBV DNA >2000–
20,000 IU/mL (i.e. >3.3–4.3 Log10 IU/mL), a persistent or intermittent increase in level 
of aminotransferase, and specific features of liver biopsies.9, 13, 14 Patients with viral 
loads below 2000 IU/mL are generally considered to be inactive carriers, although there 
is controversy over this value. 
The level of HBV DNA has prognostic value. A chronically high level of HBV DNA 
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is associated with a significant risk of progression to cirrhosis and hepatocellular 
carcinoma67, 68. However, no HBV DNA threshold has been established that has a strong 
predictive value for the occurrence of clinical outcomes, at the individual level. 
 
Decision to Treat 
The decision to treat chronic hepatitis B is based on multiple parameters, 
including the level of HBV DNA. The European Association for the Study of the Liver 
Clinical Practice Guidelines state that HBV therapy is indicated for non-cirrhotic patients 
with an HBV DNA level >2000 IU/mL (>3.3 Log10 IU/mL), serum levels of alanine 
aminotransferase (ALT) activity above the upper limit of normal (ULN), and a liver 
biopsy (or a non-invasive test) that indicates moderate to severe activity (METAVIR 
grade ≥A2) and/or fibrosis (METAVIR stage ≥F2).9 Patients with compensated cirrhosis 
and detectable HBV DNA should be considered for treatment and patients with 
decompensated cirrhosis require urgent antiviral treatment, whatever the level of HBV 
replication.9 The Clinical Practice Guidelines of the American Association for the Study of 
Liver Diseases and the Asian-Pacific Association for the Study of the Liver state that 
antiviral treatment should be considered for non-cirrhotic patients with HBV DNA titers 
>20,000 IU/mL (>4.3 Log10 IU/mL) if they are HBeAg positive, or >2000 IU/mL (>3.3 
Log10 IU/mL) if they are HBeAg negative, and if they have increased serum levels of ALT 
activity (>2 x ULN), and/or a liver biopsy showing inflammation and/or fibrosis.13, 14 
Patients should not be tested for drug resistance before therapy. 
In patients with normal ALT activity, serum levels of HBV DNA and ALT should be 
measured at 3- to 6-month intervals. More frequent monitoring should be considered 
during the first year for hepatitis B e antigen (HBeAg)-negative patients with normal 
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levels of ALT and a level of HBV DNA <2000 IU/mL (<3.3 Log10 IU/mL), to confirm their 
status as inactive carriers. 
 
Choice of Therapy 
Pegylated interferon (IFN)- is considered to be the first-line treatment option 
for HBeAg-positive patients without cirrhosis who have increased levels of ALT and a 
low level of HBV DNA (<2 x 106 IU/mL, such as <6.3 Log10 IU/mL). This treatment is 
more controversial for HBeAg-negative patients with the same characteristics.9 The HBV 
genotype is a significant predictor of the response to pegylated IFN-. However, the 
individual predictive value of the HBV genotype for the outcome of pegylated IFN- 
therapy is weak and could be biased by the relationship between genotype and 
ethnicity.69, 70 
Most patients are treated with nucleoside or nucleotide analogues. The 
international liver society guidelines recommend either tenofovir or entecavir 
monotherapy as the first-line treatment for chronic hepatitis B.9, 13, 14, 71 The HBV 
genotype has no influence on the effectiveness of nucleoside/nucleotide analogues.70 
 
Monitoring Treatment  
The ideal endpoint of therapy is a sustained loss of HBsAg, with or without 
seroconversion to anti-HBs.9 However, this is rarely achieved with current drugs. The 
practical aim is therefore to reduce levels of HBV DNA as far as possible (ideally below 
10–20 IU/mL), to achieve biochemical remission and histologic improvement and 
prevent HBV-related liver disease.9, 13, 14 Treatment of HBeAg-positive patients is 
therefore monitored by assays for HBV DNA and ALT every 3 to 6 months and HBeAg 
and anti-HBe every 6 months.  
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Treatment of HBeAg-positive patients can be stopped after a consolidation period 
of 6 to 12 months following HBe seroconversion.9, 13, 14 However, durable HBe 
seroconversion, in association with low levels of HBV replication, is rare following 
treatment with nucleoside/nucleotide analogues. In HBeAg-positive patients who do not 
develop anti-HBe antibodies, and in HBe-negative patients, nucleoside/nucleotide 
analogues must be administered for life, with the aim of achieving profound and durable 
HBV DNA suppression. If HBV DNA is still detectable (>10–20 IU/mL) after 48 weeks of 
therapy, current guidelines, based on studies of modestly potent nucleoside/nucleotide 
analogues with low barriers to resistance, recommend adding a second drug with no 
viral cross-resistance to the first to prevent emergence of resistant variants. However, 
this is not necessary with entecavir or tenofovir if the HBV DNA level continues to 
decrease after week 48, because it is likely to become undetectable thereafter.72 Serial 
measurements of HBsAg levels could help identify patients who will subsequently clear 
HBsAg.  
In patients who adhere and respond to treatment, selection of resistant HBV 
variants should be suspected if virologic breakthrough occurs, defined as a re-increase 
in the HBV DNA level by 1 Log10 or more above the nadir, or as HBV DNA that becomes 
detectable after being undetectable.14, 73 A blip (single detection of a low-level of HBV 
DNA, preceded and followed by undetectable HBV DNA), should not be considered a 
virologic breakthrough. If resistance occurs, the only effective strategy is to add a second 
drug against which the selected HBV variant is not cross-resistant.9, 14 Such drug 
combinations include tenofovir and a nucleoside analogue. Identification of amino acid 
substitutions associated with resistance has little clinical value, because this information 
rarely influences the choice of therapy. Thus, resistance testing by means of classic 
sequencing or reverse hybridization is generally not recommended. The only exception 
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is HBV with the rtA181V/T substitution—it has full sensitivity to only entecavir, which 
must be combined with tenofovir. 
 
Clinical Research 
Cohort studies, surveillance studies, and clinical trials of new therapeutic 
reagents or strategies require serial measurements of HBV DNA. In research studies, 
tests for resistant variants should be systematically performed when antiviral therapy 
fails, to identify the resistant variant and characterize its nature and dynamics. Sensitive 
sequencing methods such as NGS are particularly useful for characterizing the dynamics 
of sensitive and resistant virus populations over time. Information about HBV genotype 
and core and core promoter mutations might be used in epidemiology and 
pathophysiology studies. 
 
HCV Infection 
Assays that detect antibodies against HCV, detect and quantify HCV RNA, or 
determine HCV genotype are useful for diagnosis and treatment of HCV infection. Assays 
that detect and quantify HCV core antigen are alternatives to tests for HCV RNA, but are 
not sensitive enough to use in treatment monitoring or response-guided therapy. 
Resistance testing is not useful for patient management but is widely used in clinical 
trials of DAA or host-targeted agents, in case of treatment failure. 
 
Diagnosis and Decision to Treat 
Patients are diagnosed with chronic HCV infection based on the detection of anti-
HCV antibodies by enzyme immunoassays and HCV RNA by a sensitive molecular 
biology-based technique that has a detection limit of about 10 to 15 IU/mL. 
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All treatment-naïve patients with compensated liver disease and detectable HCV 
RNA should be considered for therapy.10, 12 Assessment of liver disease severity is 
important for decision making.10, 12 Patients infected with HCV genotype 1, in whom 
pegylated IFN-α and ribavirin combination therapy failed to eradicate the virus, should 
be considered for retreatment, because they might benefit from the triple combination 
of pegylated IFN-α, ribavirin, and a protease inhibitor. 
 
Selecting Therapy 
The HCV genotype should be determined before treatment is started. Patients 
infected with HCV genotypes other than type 1 should be treated with pegylated IFN-α 
and ribavirin alone. For patients infected with genotypes 2 or 3, the dose of ribavirin is 
0.8 g/day and the treatment duration is 24 weeks; patients with genotypes 2 and 3 with 
baseline factors that indicate low responsiveness should receive weight-based 
ribavirin.10 For patients infected with genotypes 5 and 6, the dose of ribavirin is based 
on body weight, and treatment should last up to 72 weeks, depending on the virologic 
response during treatment.  
Patients infected with HCV genotype 1 who qualify for therapy should receive the 
triple combination of pegylated IFN-α, ribavirin, and either telaprevir or boceprevir. The 
subtype (1a or 1b) does not need to be determined for patients that receive the 
combination of pegylated IFN-α and ribavirin, or triple drug combinations that include a 
protease inhibitor, because genotype 1 subtypes do not affect treatment decisions with 
these therapeutic strategies.74 Further trials are needed to improve the selection of 
patients infected with HCV genotype 1 who might not need protease inhibitors, such as 
young patients with mild fibrosis, a low baseline level of HCV RNA, or the CC IL28B 
genotype.75 
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Monitoring Treatment  
The endpoint for HCV therapy is a SVR, characterized by undetectable HCV RNA 
(<10–15 IU/mL) 24 weeks after the end of treatment—this corresponds with viral 
eradication in more than 99% of cases. 
Monitoring of HCV RNA levels during treatment is key in determining virologic 
response, in guiding duration of treatment, and in deciding futility of treatment. This is 
particularly important when direct acting antivirals are used, as reviewed by Barritt and 
Fried in this issue. 
Failure of triple combination therapy to clear HCV is associated with outgrowth 
of variant populations that are resistant to the protease inhibitor used. However, 
resistance testing based on HCV sequence analysis of the protease region has no utility 
in clinical practice.76 Resistant variants are present in almost all infected patients before 
therapy begins, but technologies available in clinical virology laboratories are not 
sensitive enough to detect them;65 negative results are therefore uninterpretable. In 
addition, the profile of HCV variants at the start of therapy does not appear to affect the 
outcome of treatment when the protease inhibitor is combined with pegylated IFN-α 
and ribavirin. At the time of treatment failure (virologic breakthrough or relapse), the 
resistant population is always enriched, and phase 2 and 3 trials have reported that that 
it is dominant in 50% to 70% of patients.77,78 Resistance testing is still not indicated at 
this time because the results will have no impact on subsequent treatment decisions.76 
 
Clinical Research 
In cohort studies, surveillance studies, and clinical trials of HCV DAA or host-
targeting agents, given alone or in combination, serial HCV RNA testing is needed to 
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characterize the virologic response and detect virologic breakthrough and relapse. 
Resistance variants should always be analyzed in patients who fail to respond to 
therapy, to characterize the nature and dynamics of the selected viral populations and 
identify amino acid substitutions selected by the DAAs. When several antiviral drugs 
with different target sites and mechanisms of action are combined, all the target sites 
should be studied. Sensitive sequencing methods such as NGS are particularly useful for 
characterizing the dynamics of sensitive and resistant virus populations over time.  
 
CONCLUSION 
 New technologies are available for detecting and quantifying viral antigens and 
genomes, and for analyzing viral genome nucleotide and amino acid sequences. Real-
time target amplification (PCR or TMA) methods are well standardized and widely used 
in clinical practice to diagnose and monitor HBV and HCV infection. In contrast, NGS 
techniques are largely restricted to research laboratories. These generate large 
quantities of data; software is needed (and is being developed) that can provide 
clinicians with meaningful information.  
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FIGURE LEGENDS 
 
Figure 1. Quasispecies distribution of HBV and HCV genomes and methods to detect 
major (>10% of the viral quasispecies), intermediate, and minor (<1% of the viral 
quasispecies) viral populations. 
 
Figure 2. Current workflow for NGS methods, including (A) library preparation, (B) 
DNA capture and clonal DNA enrichment, and (C) high-throughput sequencing that can 
be achieved by polymerization, combined with detection based on pyrophosphate 
(pyrosequencing), H+ ions (pH variation) or fluorescence, or by ligation combined with 
fluorescence detection. The detected signals are transformed into readable sequences by 
integrated browser and specific software in order to yield biologically relevant 
information. 
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Table 1. Commercially Available Real-Time Target Amplification Assays for HBV DNA and HCV RNA Detection and Quantification  
 
Assay Manufacturer Method 
Automated 
extraction 
device 
Amplification 
device 
Volume 
required 
(µL) 
LLOD 
(IU/mL) 
Dynamic 
range of 
quantification 
(UI/mL) 
HBV DNA 
COBAS® TaqMan® 
HBV Test, v2.0 
Roche 
Molecular 
Systems, 
Pleasanton, CA 
Real-time 
PCR 
Manual with 
High Pure 
System Viral 
Nucleic Acid 
Kit  
COBAS® 
TaqMan 
650 L 6-10 IU/mL 
29 (1.5 Log10)-
1 x 108 (8.0 
Log10) IU/mL 
COBAS® Ampliprep-
COBAS® TaqMan® 
(CAP/CTM) HBV 
Test, v2.0 
Roche 
Molecular 
Systems, 
Pleasanton, CA 
Real-time 
PCR 
COBAS® 
AmplipPrep®  
COBAS® 
TaqMan 
650 L 20 IU/mL 
20 (1.3 Log10)-
1.7 x 108 (8.2 
Log10) IU/mL 
RealTime™ HBV 
Abbott 
Molecular, Des 
Plaines, IL 
Real-time 
PCR 
m2000SP m2000RT 
200 or  
500 L 
10 IU/mL (for 
500L) 
15 IU/mL (for 
200 L) 
10 (1.0 Log10)-
1.0 x 109 (9.0 
Log10) IU/mL 
Artus HBV QS-RGQ 
Assay* 
Qiagen, Hilden, 
Germany 
Real-time 
PCR 
QIAsymphony 
RGQ 
Rotor-Gene Q 1000 L 10.2 IU/mL 
31.6 (1.5 
Log10)-2 x 107 
(7.3 Log10) 
IU/mL 
APTIMA® HBV 
Quantitative Assay 
Gen-Probe, San 
Diego, CA 
Real-time 
TMA 
Panther® Available in 2012 
 38 
HCV RNA 
COBAS® TaqMan® 
HCV Test, v2.0 
Roche 
Molecular 
Systems, 
Pleasanton, CA 
Real-time 
PCR 
Manual with 
High Pure 
System Viral 
Nucleic Acid 
Kit 
COBAS® 
TaqMan 
650 L 20 IU/mL 
25 (1.4 Log10)-
3.0 x 108 to 
3.9 x 108 (8.5-
8.6 Log10) 
IU/mL 
COBAS® Ampliprep-
COBAS® TaqMan® 
(CAP/CTM) HCV 
Test, v2.0 
Roche 
Molecular 
Systems, 
Pleasanton, CA 
Real-time 
PCR 
COBAS® 
AmplipPrep 
COBAS® 
TaqMan 
650 L 15 IU/mL 
15 (1.2 Log10)-
1.0 x 108 (8.0 
Log10) IU/mL 
RealTime™ HCV 
Abbott 
Molecular, Des 
Plaines, IL 
Real-time 
PCR 
m2000SP m2000RT 
200 or  
500 L 
12 IU/mL (for 
500L) 
30 IU/mL (for 
200 L) 
12 (1.1 Log10)-
1.0 x 108 (8.0 
Log10) IU/mL 
Artus HCV QS-RGQ 
Assay* 
Qiagen, Hilden, 
Germany 
Real-time 
PCR 
QIAsymphony 
RGQ 
Rotor-Gene Q 1000 L 36.2 IU/mL 
67.6 (1.8 
Log10)-
17.7 x 106 (7,2 
Log10) IU/mL 
VERSANT HCV RNA 
1.0 Assay (kPCR) 
Siemens 
Medical 
Solutions 
Diagnostics, 
Tarrytown, NY 
Real-time 
PCR 
Sample 
Preparation 
(SP) Module  
Amplification 
and Detection 
(AD) Module 
500 L 15 IU/mL 
15 (1.2 Log10)-
1.0 x 108 (8.0 
Log10) IU/mL 
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APTIMA® HCV 
Quantitative Assays 
Gen-Probe, San 
Diego, CA 
Real-time 
TMA 
Panther® Available in 2012 
*Available only for EDTA-plasma specimens. 
IU/mL: international units per milliliter. 
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Table 2. Characteristics of NGS Techniques 
Manufacturer Sequencing device 
Technology 
(template 
preparation/ 
NGS chemistry) 
Type 
Number of 
single reads 
per run* 
(x 106) 
Number of 
nucleotides 
per run* 
(Gb) 
Maximum 
sequence 
length* 
(bp) 
Accuracy 
Applied 
Biosystems  
5500 
emPCR/ligation 
High throughput 800 9 75 
99.6-99.8% 
5500xl High throughput 1600 15 75 
Ion Torrent (ChiP 316) 
emPCR/real-time 
sequencing 
Long reads 6.2 >1 >400 99.97%* 
Illumina 
MiSeq 
Solid 
capture/reversible 
terminator 
High throughput 3.4 >1 150 
96.7-100% 
Genome Analyzer IIx High throughput 320 95 150 
HiSeq 1000 High throughput 1500 300 100 
HiSeq 2000 High throughput 3000 600 100 
454 Life 
Sciences/Roche 
Diagnostics 
GS Junior 
emPCR/pyrosequencing 
Long reads 0.1 0.035 400 99%* 
GS FLX+ Long reads 1 0.7 1000 97.4-99.9% 
Pacific 
Biosciences/Gen-
Probe 
PacBio RS 
Single molecule/real-
time sequencing 
Long reads 0.035 0.045 1200 99.99%* 
*Information provided by the manufacturers; Gb, gigabase; bp, base pair; emPCR, emulsion PCR 
